ARTICLE | Finance

Excitement for CytomX

With new B round, CytomX aiming for several INDs from antibody platform

September 27, 2010 7:00 AM UTC

Third Rock Ventures expects the $30 million B round it led last week for CytomX Therapeutics LLC will be enough to support several IND filings.

CytomX plans to develop a form of antibodies that can be activated and controlled, and expects to pursue new targets and improve products against known targets. The hope is the platform will produce protease-activated antibody therapeutics with a greater level of tissue selectivity than conventional antibodies...